My watch list
my.bionity.com  
Login  

Approval of Additional Indication of NESINA: Combination Therapy with Thiazolidinediones for Type 2 Diabetes in Japan

24-Aug-2010

Takeda Pharmaceutical Company Limited announced that an additional indication for “NESINA®” (generic name: Alogliptin), combination therapy with thiazolidinediones for type 2 diabetes, was approved by the Japanese Ministry of Health, Labour and Welfare.

NESINA, a dipeptidyl peptidase-IV (DPP-4) inhibitor created by Takeda San Diego, Inc., Takeda's wholly-owned subsidiary, became available on the Japanese market in June 2010. It exhibits extremely high selectivity for DPP-4 inhibition, and a once daily dose with NESINA provides outstanding hypoglycemic benefits. NESINA slows the inactivation of the incretin hormones GLP-1 (glucagon-like peptide-1) which plays a major role in regulating blood glucose levels and the products has the potential to improve pancreatic beta-cell function.

NESINA is the only DPP-4 inhibitor that is approved for administration combined with alpha-glucosidase inhibitors in Japan, and the approval this time gives the option of combining DPP-4 with thiazolidinediones. Thiazolidinediones reduce insulin resistance, one of the pathologic conditions specifically found in type 2 diabetes, and Actos® (generic name: Pioglitazone) is the only approved thiazolidinedione in Japan marketed by Takeda. This additional indication of combination therapy is expected to improve two major pathologic conditions associated with type 2 diabetes: a decrease in insulin secretion and insulin resistance. Hence, this will provide a broader range of treatment options for diabetic patients and healthcare professionals.

Facts, background information, dossiers
More about Takeda Pharma
More about Takeda
  • News

    Takeda to invest more than 100 million Euros in dengue vaccine manufacturing plant

    Takeda Pharmaceutical Company Limited announced that it will invest more than 100 Million Euros to build a new manufacturing plant for its dengue vaccine candidate in Singen, Germany. This represents a major step by Takeda toward meeting important unmet needs in dengue prevention. According ... more

    UCL and Takeda announce a new research partnership

    UCL (University College London) and Takeda Pharmaceutical Company Limited announced a new research collaboration to identify and validate novel target genes for the treatment of neurodegenerative disease. This collaboration will focus on mechanistic approaches for the identification of gene ... more

    Evotec to Collaborate with Takeda Cambridge for Multi-target Hit Identification

    Evotec AG  announced that it has entered into a collaboration with Takeda Cambridge Limited, to identify small molecule modulators against GPCR and Protease targets involved in various CNS and Metabolic diseases.Evotec will apply its state-of-the-art Screening Platform and proprietary GPCR ... more

  • Companies

    Takeda San Diego, Inc.

    Takeda San Diego (TSD) is Takeda's global center for excellence in structure-based drug discovery. TSD integrates cutting-edge protein crystallography and drug discovery technologies to efficiently generate Investigational New Drug (IND) candidates for the treatment of metabolic diseases an ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE